Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling

Lifestyle factors are important drivers of chronic diseases, including cardiovascular syndromes, with low grade inflammation as a central player. Attenuating myeloperoxidase (MPO) activity, an inflammatory enzyme associated with obesity, hypertension and heart failure, could have protective effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Piek, Arnold, Koonen, Debby P. Y., Schouten, Elisabeth-Maria, Lindtstedt, Eva L., Michaëlsson, Erik, de Boer, Rudolf A., Silljé, Herman H. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904581/
https://www.ncbi.nlm.nih.gov/pubmed/31822739
http://dx.doi.org/10.1038/s41598-019-55263-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904581/
https://www.ncbi.nlm.nih.gov/pubmed/31822739
http://dx.doi.org/10.1038/s41598-019-55263-y

Ejemplares similares